Table 1.

Toxicity evaluation from multiple courses of US-delivered chemotherapy.

	Nontumor-bearing mice		i.c. glioma PDX model^a
Treatment	Mortality	Signs of CNS Pathology	Mortality	Signs of CNS pathology	Total survival (%)
Ultrasound only	0/8	2/4 Small focal white matter vacuolation (WMV), Hemosiderin-laden macrophages (HLM)	0/19		27/27 (100%)
Ultrasound + Cremophor EL PTX (12 mg/kg)	4/7	3/4 severe necrosis, hemorrhage, Diffuse axonal injury (DAI), hippocampal damage			3/7 (42%)
Ultrasound + Cremophor EL (5% in Saline)	3/8	1/3 DAI 2/3 small focal WMV			5/8 (62.5%)
Ultrasound + Abraxane (12 mg/kg)	1/6	3/4 Focal WMV	0/20		25/26 (96%)
Ultrasound + Abraxane (24 mg/kg)	0/5	1/3 HLM	5/21	1/3 cytotoxic edema 1/3 DAI 1/3 focal WMV	21/26 (81%)
Ultrasound + Abraxane^b (24 mg/kg)			0/10		10/10 (100%)

↵^aIn intracranial glioma PDX model mice, deaths were considered due to treatment if the day of death was considered significantly different from control untreated tumor-bearing mice (P < 0.0005).
↵^bMice received treatment twice a week (MTh) × 4 weeks instead of 8 courses of treatment over 3 weeks.